Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $63.00 Price Target at Jefferies Financial Group

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target decreased by Jefferies Financial Group from $114.00 to $63.00 in a report published on Tuesday,Benzinga reports. Jefferies Financial Group currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently issued reports on RARE. Weiss Ratings restated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, October 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $105.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Barclays lowered their target price on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, November 24th. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 9th. Finally, TD Cowen reduced their price target on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Fifteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $75.19.

Ultragenyx Pharmaceutical Trading Up 15.5%

RARE stock opened at $22.78 on Tuesday. The stock has a market cap of $2.20 billion, a PE ratio of -3.84 and a beta of 0.16. Ultragenyx Pharmaceutical has a 12 month low of $18.41 and a 12 month high of $46.50. The company has a 50-day moving average price of $33.43 and a 200 day moving average price of $32.01.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.58). The firm had revenue of $159.93 million during the quarter, compared to the consensus estimate of $167.42 million. Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The firm’s revenue for the quarter was up 14.6% on a year-over-year basis. During the same period in the previous year, the business earned ($1.40) EPS. Sell-side analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Activity

In other news, CFO Howard Horn sold 7,942 shares of the stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $31.51, for a total transaction of $250,252.42. Following the transaction, the chief financial officer directly owned 98,227 shares in the company, valued at approximately $3,095,132.77. This trade represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 11,108 shares of company stock worth $365,262 in the last 90 days. 5.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Large investors have recently added to or reduced their stakes in the company. Hudson Bay Capital Management LP lifted its position in Ultragenyx Pharmaceutical by 2.4% during the third quarter. Hudson Bay Capital Management LP now owns 265,000 shares of the biopharmaceutical company’s stock valued at $7,971,000 after acquiring an additional 6,319 shares during the last quarter. Danske Bank A S purchased a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth about $39,000. Jacobs Levy Equity Management Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 614.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after acquiring an additional 1,864,164 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its position in shares of Ultragenyx Pharmaceutical by 2.0% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 26,932 shares of the biopharmaceutical company’s stock valued at $817,000 after purchasing an additional 534 shares during the last quarter. Finally, Voloridge Investment Management LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth $14,516,000. 97.67% of the stock is currently owned by institutional investors.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx completed the rolling BLA submission to the FDA for DTX401 (pariglasgene brecaparvovec) for GSDIa — the filing now includes CMC, clinical and non‑clinical modules; the program has RMAT/ Fast Track/orphan designations and Phase 3 data across ~52 patients showing reduced cornstarch use and improved glycemic control. This is a multi‑year commercial catalyst if approved and would be the first therapy addressing the underlying cause of GSDIa. GlobeNewswire: BLA Submission
• Positive Sentiment: Unusual options activity: an above‑average number of call contracts traded, indicating speculative/hedged bullish interest that may amplify intraday upside.
• Neutral Sentiment: Analysts revised price targets lower after the recent volatility but largely maintained Outperform/Buy ratings (examples: Baird, Leerink, Jefferies, Wells Fargo), leaving materially higher median targets than the current price — reflects confidence in longer‑term pipeline value but acknowledges near‑term uncertainty. Benzinga: Analyst Moves
• Neutral Sentiment: Small insider sale disclosed (CAO sold 85 shares) — immaterial to ownership but noted by market participants. SEC filing: SEC Filing
• Negative Sentiment: Major negative catalyst: Ultragenyx and partner Mereo announced that two Phase 3 studies of setrusumab in osteogenesis imperfecta failed to meet primary endpoints (no reduction in fracture rate), which precipitated a steep market decline and prompted operational retrenchment announcements. This materially reduces near‑term revenue prospects and created significant investor uncertainty. Reuters: Setrusumab Phase 3 Failure
• Negative Sentiment: Two law firms (Pomerantz, Portnoy) announced investigations into Ultragenyx that may lead to securities litigation related to the trial misses and disclosures — potential legal overhang and expense risk. GlobeNewswire: Pomerantz GlobeNewswire: Portnoy
• Negative Sentiment: Market mechanics: trading was halted as key news hit and the shares experienced extreme intraday volatility and high volume, reflecting rapid re‑pricing and elevated risk for short‑term holders. Coverage and headlines amplified the selloff. MarketWatch: Shares Slide

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.